CA3000215A1 - Antigen-binding proteins that activate the leptin receptor - Google Patents

Antigen-binding proteins that activate the leptin receptor Download PDF

Info

Publication number
CA3000215A1
CA3000215A1 CA3000215A CA3000215A CA3000215A1 CA 3000215 A1 CA3000215 A1 CA 3000215A1 CA 3000215 A CA3000215 A CA 3000215A CA 3000215 A CA3000215 A CA 3000215A CA 3000215 A1 CA3000215 A1 CA 3000215A1
Authority
CA
Canada
Prior art keywords
lepr
antibody
antigen
antibodies
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3000215A
Other languages
English (en)
French (fr)
Inventor
Jesper Gromada
Panayiotis Stevis
Judith Altarejos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57184864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3000215(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CA3000215A1 publication Critical patent/CA3000215A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA3000215A 2015-10-12 2016-10-11 Antigen-binding proteins that activate the leptin receptor Pending CA3000215A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562240021P 2015-10-12 2015-10-12
US62/240,021 2015-10-12
US201662359757P 2016-07-08 2016-07-08
US62/359,757 2016-07-08
US201662375495P 2016-08-16 2016-08-16
US62/375,495 2016-08-16
US201662393143P 2016-09-12 2016-09-12
US62/393,143 2016-09-12
PCT/US2016/056465 WO2017066204A1 (en) 2015-10-12 2016-10-11 Antigen-binding proteins that activate the leptin receptor

Publications (1)

Publication Number Publication Date
CA3000215A1 true CA3000215A1 (en) 2017-04-20

Family

ID=57184864

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3000215A Pending CA3000215A1 (en) 2015-10-12 2016-10-11 Antigen-binding proteins that activate the leptin receptor

Country Status (32)

Country Link
US (6) US10023644B2 (OSRAM)
EP (2) EP3362477B1 (OSRAM)
JP (5) JP7034068B2 (OSRAM)
KR (2) KR20180070609A (OSRAM)
CN (1) CN108368177B (OSRAM)
AU (2) AU2016338851B2 (OSRAM)
BR (1) BR112018007318A2 (OSRAM)
CA (1) CA3000215A1 (OSRAM)
CL (2) CL2018000946A1 (OSRAM)
CO (1) CO2018003852A2 (OSRAM)
CY (1) CY1125102T1 (OSRAM)
DK (1) DK3362477T3 (OSRAM)
EA (1) EA201890928A1 (OSRAM)
ES (1) ES2908574T3 (OSRAM)
HR (1) HRP20220426T8 (OSRAM)
HU (1) HUE058280T2 (OSRAM)
IL (3) IL300961B2 (OSRAM)
LT (1) LT3362477T (OSRAM)
MX (2) MX2018004531A (OSRAM)
MY (1) MY187975A (OSRAM)
PH (1) PH12018500663A1 (OSRAM)
PL (1) PL3362477T3 (OSRAM)
PT (1) PT3362477T (OSRAM)
RS (1) RS63061B1 (OSRAM)
SG (1) SG10201913432RA (OSRAM)
SI (1) SI3362477T1 (OSRAM)
SM (1) SMT202200125T1 (OSRAM)
TW (3) TWI752920B (OSRAM)
UA (1) UA124419C2 (OSRAM)
UY (1) UY36942A (OSRAM)
WO (1) WO2017066204A1 (OSRAM)
ZA (1) ZA201801975B (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI752920B (zh) * 2015-10-12 2022-01-21 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
EP4613772A3 (en) * 2016-11-08 2025-12-24 Regeneron Pharmaceuticals, Inc. Antigen-binding proteins that antagonize leptin receptor
CN115025327B (zh) 2017-05-05 2024-06-28 里珍纳龙药品有限公司 自动注射器和相关使用方法
CN111542540A (zh) 2017-12-18 2020-08-14 瑞泽恩制药公司 结合瘦蛋白受体和/或gp130的双特异性抗原结合分子及其使用方法
HRP20250986T1 (hr) * 2018-04-06 2025-10-24 Regeneron Pharmaceuticals, Inc. Antitijelo agonista leptinskog receptora za upotrebu u povećanju koštane mase kod osobe koja pati od metaboličke disfunkcije ili hipoleptinemije
PL3868743T3 (pl) * 2018-10-11 2023-08-14 Sumitomo Chemical Company Limited System oczyszczania tlenku propylenu i sposób wytwarzania tlenku propylenu
US12404346B2 (en) 2019-01-31 2025-09-02 Siemens Healthcare Diagnostics Inc. Anti-naloxone and anti-naltrexone monoclonal antibodies and methods of production and use thereof
US20220288169A1 (en) * 2019-05-24 2022-09-15 The Board of Supervisors of Louisiana State University and Agriculyural and Mechanical College Compositions and methods for the treatment and prevention of hypoglycemic complications
AU2019452639A1 (en) * 2019-07-02 2022-02-03 Shanghaitech University Antibody to leptin receptor
KR102863417B1 (ko) 2019-12-03 2025-09-24 마이크론 테크놀로지, 인크. 저장 디바이스를 위한 캐시 아키텍처
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
AU2021343444A1 (en) 2020-09-15 2023-04-20 Regeneron Pharmaceuticals, Inc. Use of lepr agonists for pain
DK4294257T3 (da) 2021-02-22 2025-12-08 Regeneron Pharma Fremgangsmåde til diagnosticering og behandling af partiel lipodystrofi
CN114456124B (zh) * 2021-12-30 2023-04-21 华南农业大学 一种新利司他半抗原、人工抗原、抗体及其制备方法和应用
AR132984A1 (es) 2023-06-16 2025-08-13 Regeneron Pharma Empaque de dispositivo médico y métodos relacionados
TW202529831A (zh) 2023-10-02 2025-08-01 美商再生元醫藥公司 藥物遞輸裝置安全系統
JP2025148269A (ja) 2024-03-15 2025-10-07 イーライ リリー アンド カンパニー 肥満を治療するための単独又は併用療法としてのレプチン受容体アゴニスト抗体
WO2025227054A1 (en) * 2024-04-25 2025-10-30 The Board Of Regents Of The University Of Texas System Monoclonal antibodies binding to leptin and uses thereof
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6451523B1 (en) 1994-09-14 2002-09-17 Interneuron Pharmaceuticals, Inc. Detection of a leptin receptor variant and methods for regulating obesity
US5643748A (en) 1994-09-14 1997-07-01 Progenitor, Inc. HU-B1.219, a novel human hematopoietin receptor
US5912123A (en) 1994-09-14 1999-06-15 Progenitor, Inc. Detection of the leptin receptor in reproductive organs and methods for regulating reproductive biology
US5856098A (en) 1994-09-14 1999-01-05 Progenitor, Inc. Detection of a leptin receptor variant
US6482927B1 (en) 1995-11-27 2002-11-19 Millennium Pharmaceuticals, Inc. Chimeric proteins comprising the extracellular domain of murine Ob receptor
US6977240B1 (en) * 1995-11-27 2005-12-20 Millenium Pharmaceuticals, Inc. Methods of using the OB receptor antibodies to treat bodyweight disorders
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
WO1997025425A1 (en) 1996-01-08 1997-07-17 Genentech, Inc. Wsx receptor and ligands
AU2476301A (en) 1996-01-16 2001-05-24 Rockefeller University, The DB the receptor for leptin nucleic acids encoding the receptor, and uses thereof
US7063958B1 (en) 1996-01-16 2006-06-20 The Rockefeller University Nucleic acids db, the receptor for leptin
AU1833197A (en) 1996-01-18 1997-08-11 Progenitor, Inc. Detection of a leptin receptor variant and methods for regulating obesity
DK0892849T3 (da) 1996-01-23 2006-07-24 Indevus Pharmaceuticals Inc Fremgangsmåde til anvendelse af obese-genet og dets genprodukt til stimulering af hæmatopoietisk udvikling
AUPN780096A0 (en) * 1996-01-30 1996-02-22 Medvet Science Pty. Ltd. Cytokine antagonists and agonists
US7067472B1 (en) 1996-06-04 2006-06-27 The Scripps Research Institute Diagnostic and therapeutic methods related to regulating energy mobilization with OB protein and OB antibodies
US5965521A (en) 1997-02-25 1999-10-12 Eli Lilly Company Pulsatile delivery of leptin receptor ligands
IL120733A0 (en) 1997-04-29 1997-08-14 Yeda Res & Dev Leptin as an inhibitor of cell proliferation
US6696411B1 (en) 1998-04-22 2004-02-24 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
AU767068B2 (en) 1999-06-11 2003-10-30 Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of leptin activity
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040253242A1 (en) 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
EP1444516B1 (en) 2001-10-22 2010-07-21 Amgen, Inc. Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment
EP2002827A2 (en) * 2001-12-05 2008-12-17 The Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of sympathetic tone
FR2852397B1 (fr) 2003-03-10 2005-04-29 Utilisation des genes leprotl 1 et ob-rgrp pour le criblage de composes actifs sur la prise ou la perte de poids ou le diabete d'un sujet humain ou animal.
DE10353593A1 (de) 2003-11-17 2005-06-23 Klinikum der Universität München Großhadern-Innenstadt Leptinantagonist und Verfahren zur quantitativen Messung von Leptin
WO2005056602A1 (ja) * 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha アゴニスト活性を有する改変抗体のスクリーニング方法
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
US8969291B2 (en) 2004-10-08 2015-03-03 Enzo Therapeutics, Inc. Methods for decreasing leptin levels or activity for treating inflammation
US7863240B2 (en) 2004-10-08 2011-01-04 Enzo Therapeutics, Inc. Methods and uses of leptin in hepatocellular carcinoma
CA2585549A1 (en) 2004-11-18 2006-05-26 Vib Vzw Novel type leptin receptor antagonist
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
GB0715216D0 (en) 2007-08-03 2007-09-12 Asterion Ltd Leptin
US20100260772A1 (en) 2007-09-28 2010-10-14 The Trustees Of Columbia University In The City Of New York Methods for treating or preventing diseases associated with low bone mass
DK2356270T3 (da) 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
PT2564695E (pt) 2009-07-08 2015-06-03 Kymab Ltd Modelos animais e moléculas terapêuticas
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
DK2505654T4 (da) 2010-02-08 2020-07-27 Regeneron Pharma Mus med fælles letkæde
MX355060B (es) 2010-11-17 2018-04-03 Chugai Pharmaceutical Co Ltd Molecula multiespecifica de union a antigeno que tiene funcion alternativa a la funcion del factor viii de coagulacion sanguinea.
JO3756B1 (ar) * 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
MX2013009151A (es) 2011-02-10 2013-08-29 Roche Glycart Ag Inmunoterapia mejorada.
SI2738258T2 (sl) 2011-02-25 2023-05-31 Regeneron Pharmaceuticals, Inc. Miši ADAM6
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
MY172718A (en) 2011-08-05 2019-12-11 Regeneron Pharma Humanized universal light chain mice
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
SG11201407644UA (en) 2012-06-05 2014-12-30 Regeneron Pharma Methods for making fully human bispecific antibodies using a common light chain
EP2895513B1 (en) 2012-09-12 2018-05-23 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
TW201920262A (zh) * 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
EP3108255B1 (en) 2014-02-18 2020-08-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of diseases mediated by the nrp-1/obr complex signaling pathway
TWI752920B (zh) * 2015-10-12 2022-01-21 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
EP4613772A3 (en) 2016-11-08 2025-12-24 Regeneron Pharmaceuticals, Inc. Antigen-binding proteins that antagonize leptin receptor
CN107760761A (zh) 2017-11-10 2018-03-06 江苏省农业科学院 一种加强瘦素激发lepr信号转导的方法
CN111542540A (zh) 2017-12-18 2020-08-14 瑞泽恩制药公司 结合瘦蛋白受体和/或gp130的双特异性抗原结合分子及其使用方法
HRP20250986T1 (hr) 2018-04-06 2025-10-24 Regeneron Pharmaceuticals, Inc. Antitijelo agonista leptinskog receptora za upotrebu u povećanju koštane mase kod osobe koja pati od metaboličke disfunkcije ili hipoleptinemije

Also Published As

Publication number Publication date
JP2023002713A (ja) 2023-01-10
TW201726737A (zh) 2017-08-01
IL300961B2 (en) 2025-04-01
US12275792B2 (en) 2025-04-15
PL3362477T3 (pl) 2022-05-02
SI3362477T1 (sl) 2022-04-29
NZ741097A (en) 2025-06-27
TW202417497A (zh) 2024-05-01
HK1254862A1 (zh) 2019-07-26
IL258448B2 (en) 2023-08-01
EP4071173A1 (en) 2022-10-12
PH12018500663A1 (en) 2018-10-01
EA201890928A1 (ru) 2018-09-28
UY36942A (es) 2017-05-31
US20200031946A1 (en) 2020-01-30
US20250051465A1 (en) 2025-02-13
US20180282421A1 (en) 2018-10-04
JP7165225B2 (ja) 2022-11-02
EP3362477A1 (en) 2018-08-22
IL316563A (en) 2024-12-01
IL300961B1 (en) 2024-12-01
CN108368177B (zh) 2022-05-31
BR112018007318A2 (en) 2018-10-23
US10023644B2 (en) 2018-07-17
JP7699191B2 (ja) 2025-06-26
HRP20220426T8 (hr) 2022-06-10
KR20180070609A (ko) 2018-06-26
JP7436603B2 (ja) 2024-02-21
AU2016338851B2 (en) 2023-08-10
RS63061B1 (sr) 2022-04-29
US10618968B2 (en) 2020-04-14
JP2024042114A (ja) 2024-03-27
JP7759417B2 (ja) 2025-10-23
US20170101477A1 (en) 2017-04-13
CN108368177A (zh) 2018-08-03
ZA201801975B (en) 2020-07-29
PT3362477T (pt) 2022-03-02
KR20250069979A (ko) 2025-05-20
EP3362477B1 (en) 2022-01-05
UA124419C2 (uk) 2021-09-15
DK3362477T3 (da) 2022-03-07
ES2908574T3 (es) 2022-05-03
JP2018535948A (ja) 2018-12-06
CL2018000946A1 (es) 2018-12-14
AU2016338851A1 (en) 2018-04-19
JP2024026230A (ja) 2024-02-28
SMT202200125T1 (it) 2022-05-12
TWI824372B (zh) 2023-12-01
JP7034068B2 (ja) 2022-03-11
IL300961A (en) 2023-04-01
TWI752920B (zh) 2022-01-21
CY1125102T1 (el) 2024-02-16
US20220112293A1 (en) 2022-04-14
NZ780753A (en) 2025-06-27
LT3362477T (lt) 2022-03-10
MY187975A (en) 2021-11-05
HRP20220426T1 (hr) 2022-05-27
MX2023000738A (es) 2023-02-13
CL2019001434A1 (es) 2019-10-11
IL258448B1 (en) 2023-04-01
AU2023206125A1 (en) 2023-08-31
WO2017066204A1 (en) 2017-04-20
US10253102B2 (en) 2019-04-09
NZ780754A (en) 2025-06-27
SG10201913432RA (en) 2020-03-30
JP2021090461A (ja) 2021-06-17
CO2018003852A2 (es) 2018-07-10
US20180282420A1 (en) 2018-10-04
TW202216785A (zh) 2022-05-01
MX2018004531A (es) 2018-09-12
HUE058280T2 (hu) 2022-07-28
IL258448A (en) 2018-05-31

Similar Documents

Publication Publication Date Title
US12275792B2 (en) Antigen-binding proteins that activate the leptin receptor
EP3538554B1 (en) Antigen-binding proteins that antagonize leptin receptor
HK40072673A (en) Antigen-binding proteins that activate the leptin receptor
HK1254862B (en) Antigen-binding proteins that activate the leptin receptor
EA048830B1 (ru) Полинуклеотиды, кодирующие антитела, которые связываются с лептиновым рецептором, и способ получения таких антител
EA041859B1 (ru) Антигенсвязывающие белки, которые активируют лептиновый рецептор
BR122025018407A2 (pt) Anticorpo isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, e, uso de uma composição farmacêutica

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211001

EEER Examination request

Effective date: 20211001

EEER Examination request

Effective date: 20211001

EEER Examination request

Effective date: 20211001

EEER Examination request

Effective date: 20211001

EEER Examination request

Effective date: 20211001

EEER Examination request

Effective date: 20211001